← brief for 2026-08-20 · Slowing decline

Trends in utilization of glucagon-like peptide‑1 receptor agonists, sodium-glucose cotransporter‑2 inhibitors, and metabolic bariatric surgery in U.S. Adults with diabetes and obesity.

Article A Peer reviewed Meta-analysis or large trial

Key takeaways

The use of GLP-1 drugs and SGLT2 inhibitors is rising among US adults with diabetes and obesity. These drugs help slow kidney disease decline by reducing protein in the urine. This study used data from 100,000 people over 5 years.

Who did this work

Wartko PD · Zhang R · Johnson E · Begle C · Bobb JF · Chen C · Singh A · Ross L · O'Connor PJ · Arterburn D · McCoy RG

Source

Article · PubMed, the drug frontier · 2026 Aug 20
https://pubmed.ncbi.nlm.nih.gov/42624330/